-- Alan Mozes
MONDAY, April 4 (HealthDay News) -- A minimally invasive
treatment for mitral regurgitation -- a leaky heart valve condition
common among seniors -- appears to be as effective as open-heart
surgery, new research suggests.
While both interventions take about two hours to perform, the
newer alternative to open-heart surgery tackles mitral
regurgitation by means of a catheter-enabled insertion of a tiny
clothespin-like device, called a "MitraClip," which is threaded
through a major artery into the heart to clamp the leak.
Both methods achieve roughly the same degree of symptom relief,
the study found. But the MitraClip approach seems to get the job
done while requiring far less hospitalization and recovery
"After getting a MitraClip, patients spend one or two nights in the hospital versus five to seven days after open-heart surgery, and they're back to full activity immediately," study co-author Dr. Ted Feldman, director of the cardiac catheterization laboratory at NorthShore University HealthSystem in Evanston, Ill., said in a news release from the American College of Cardiology. "Traditional open-heart surgery has a recovery time of one to three months. The contrast is pretty striking."
Feldman and his colleagues are slated to present their findings
Monday at the American College of Cardiology meeting, in New
Orleans. Experts note that research presented at meetings isn't
subjected to the same type of scrutiny given to research published
in peer-reviewed journals.
The study was funded by Evalve Inc., the maker of the
The authors noted that among those aged 55 and up, one in five
have clinical indications of mitral regurgitation, which results
when the mitral valve in the heart stops closing properly,
permitting blood to leak back into the heart, and causing the heart
to pump hard as a result. Symptoms included breathing difficulty,
fatigue, dizziness, foot and leg swelling, coughing and/or
Yet among the quarter-million Americans who are diagnosed each
year with the condition, only one-fifth actually undergo open-heart
surgery to repair or replace the valve due to a general reluctance
to submit to such an invasive and risky procedure.
As a consequence, many patients turn to medications for symptom
relief as their ability to engage in routine physical activity
The MitraClip procedure involves the guidance of a tiny clip (or
sometimes two clips) through the groin and femoral artery into the
heart, where the valve is correctively clamped.
The current study involved 279 patients being treated for mitral
regurgitation in 37 different health care facilities across North
After randomly assigning patients to one or the other
intervention, the investigators found that while nearly 63 percent
of the MitraClip group performed well in terms of survival,
symptoms and need for further treatment, that figure was only
slightly higher (about 66 percent) among the open-heart surgery
They further noted that among the MitraClip patients, 78 percent
did not need additional surgery in the two years following their
What's more, far fewer of the MitraClip patients experienced
side effects (such as the need for subsequent blood transfusions)
compared with the open-heart group (15 vs. nearly 48 percent).
The team noted that while a replacement heart valve lasts for 35
years, a MitraClip valve repair will endure for about 15 years. And
patients undergoing the former must take the blood-thinning drug
warfarin for life, but clip patients only have to follow a
one-month regimen of the drug clopidogrel, followed by a six months
Feldman and his team concluded that while further long-range
evaluation is needed, the clip method appears to be a viable option
for some mitral regurgitation patients.
Dr. James Slater, director of the cardiac catheterization
laboratory at NYU Langone Medical Center, tested the MitraClip in a
clinical trial and had this to say: "In my opinion, the MitraClip
is a major advance in the treatment of mitral regurgitation for
some patients. Although the degree of reduction in valve leaking is
not as great with the MitraClip as it is with conventional valve
surgery, MitraClip patients have similar improvements in their
symptoms, and at two years 78 percent did not require conversion to
Slater added, "For older patients especially, the MitraClip
technology frequently offers the same gain, but with much less
For more on mitral regurgitation, visit the
U.S. National Library of Medicine.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.